| Disease (Protein) . | Author (References) . | Number of Patients . | Proportion of Patients With pTDP-43 Expression (%) . | Brain Distribution of pTDP-43 . | Morphology of pTDP-43 . | Association With Disease Protein . | pTDP-43 Expression Type . |
|---|---|---|---|---|---|---|---|
| PD, DLB (α-synuclein) | Yasuda et al (17) | 10 | 10 | Hippocampus, entorhinal | NCI | Colocalizaion(+) | Aging type |
| Higashi et al (18) | 11 | 45 | Amygdala, hippocampus, entorhinal | NCI, DN | Aging type | ||
| Arai et al (19) | 15 | 53 | Amygdala, hippocampus, entorhinal | NCI, DN | Colocalization(+) | Aging type | |
| Uchino et al (20) | 11 | 72.7 | Hippocampus, amygdala, medulla | DN, NCI, GCI | Aging type | ||
| McAleese et al (21) | 15 | 33.3 | Amygdala, hippocampus | NCI | Aging type | ||
| Buciuc et al (22) | 395 | 37 | Hippocampus | not examined | |||
| Uemura et al (23) | 313 | 21 | Amygdala, hippocampus, entorhinal (LATE) | NCI | Aging type | ||
| Guam PDC (tau) | Hasegawa et al (24) | 6 | 100 | Hippocampus | NCI, DN | Aging type | |
| Geser et al (25) | 26 | 46.2 | Amygdala, hippocampus, entorhinal | NCI, GCI | Aging type | ||
| Miklossy et al (26) | 35 | 100 | Amygdala, hippocampus, entorhinal | NCI | Aging type | ||
| PSP (tau) | King et al (27) | 5 | 20 | Neocortex | NCI | Aging type | |
| Yokota et al (12) | 19 | 26 | Amygdala, hippocampus, entorhinal | NCI | Colocalization(+) | Aging type | |
| Kertesz et al (28) | 1 | 0 | None | ||||
| Koga et al (29) | 945 | 6 | Amygdala, hippocampus, PSP lesions (substantia nigra, subthalamic nucleus, globus pallidus) | NCI, DN, NII | Neurodegenerative type | ||
| CBD (tau) | Uryu et al (30) | 39 | 15.4 | Hippocampus, entorhinal, temporal-frontal cortex | DN | Aging type | |
| Yokota et al (12) | 12 | 17 | Amygdala, hippocampus, entorhinal | NCI | Colocalization(−) | Aging type | |
| Kouri et al (31) | 1 | 100 | Olivary nucleus | NCI | |||
| Yamashita et al (32) | 1 | 100 | CBD lesions (cerebral cortex, pons, medulla oblongata) | NCI | Colocalization(+) | Neurodegenerative type | |
| Koga et al (33) | 187 | 45 | CBD lesions (midbrain tegmentum, subthalamic nucleus, pontine tegmentum, substantia nigra) | NCI | Neurodegenerative type | ||
| Sainouchi et al (34) | 10 | 90 | CBD lesions (putamen, globus pallidus, thalamus, subthalamic nucleus, pontine tegmentum) | NCI, GCI, DN | Colocalization(+) | Neurodegenerative type | |
| MSA (α-synuclein) | Geser et al (35) | 29 | rare | Amygdala, hippocampus, entorhinal | DN, GCI, NCI | Aging type | |
| Sousa et al (36) | 1 | 0 | None | ||||
| Koga et al (37) | 186 | 7 | Amygdala, hippocampus | GCI | Colocalization(+) | Aging type | |
| Nwabuobi et al (38) | 1 | 100 | Lenticular nucleus, paracentral cortex | NCI, GCI | Colocalization(+) | Aging type | |
| AGD (tau) | Fujishiro et al (39) | 15 | 60 | Amygdala, hippocampus, entorhinal | NCI, GCI | Aging type | |
| Uchino et al (20) | 11 | 54.5 | Hippocampus, amygdala | DN, NCI, GCI | Aging type | ||
| SCA2 | Toyoshima et al (14) | 1 | 100 | SCA2 lesions (motor cortex, thalamus, red nucleus, pons, inferior olive) | NCI | Neurodegenerative type | |
| SCA3 | Tan et al (40) | 10 | 100 | Cranial nucleus, spinal cord | NCI | Neurodegenerative type | |
| Huntington (polyglutamine) | Schwab et al (41) | 10 | 100 | Huntington lesions (frontal and temporal cortex) | NCI, DN | Colocalization(+) | Neurodegenerative type |
| Tada et al (42) | 4 | 100 | Huntington lesions (cerebral cortex, thalamus, hypoglossal nucleus, anterior horn) | NCI, DN | Colocalization(−) | Neurodegenerative type |
| Disease (Protein) . | Author (References) . | Number of Patients . | Proportion of Patients With pTDP-43 Expression (%) . | Brain Distribution of pTDP-43 . | Morphology of pTDP-43 . | Association With Disease Protein . | pTDP-43 Expression Type . |
|---|---|---|---|---|---|---|---|
| PD, DLB (α-synuclein) | Yasuda et al (17) | 10 | 10 | Hippocampus, entorhinal | NCI | Colocalizaion(+) | Aging type |
| Higashi et al (18) | 11 | 45 | Amygdala, hippocampus, entorhinal | NCI, DN | Aging type | ||
| Arai et al (19) | 15 | 53 | Amygdala, hippocampus, entorhinal | NCI, DN | Colocalization(+) | Aging type | |
| Uchino et al (20) | 11 | 72.7 | Hippocampus, amygdala, medulla | DN, NCI, GCI | Aging type | ||
| McAleese et al (21) | 15 | 33.3 | Amygdala, hippocampus | NCI | Aging type | ||
| Buciuc et al (22) | 395 | 37 | Hippocampus | not examined | |||
| Uemura et al (23) | 313 | 21 | Amygdala, hippocampus, entorhinal (LATE) | NCI | Aging type | ||
| Guam PDC (tau) | Hasegawa et al (24) | 6 | 100 | Hippocampus | NCI, DN | Aging type | |
| Geser et al (25) | 26 | 46.2 | Amygdala, hippocampus, entorhinal | NCI, GCI | Aging type | ||
| Miklossy et al (26) | 35 | 100 | Amygdala, hippocampus, entorhinal | NCI | Aging type | ||
| PSP (tau) | King et al (27) | 5 | 20 | Neocortex | NCI | Aging type | |
| Yokota et al (12) | 19 | 26 | Amygdala, hippocampus, entorhinal | NCI | Colocalization(+) | Aging type | |
| Kertesz et al (28) | 1 | 0 | None | ||||
| Koga et al (29) | 945 | 6 | Amygdala, hippocampus, PSP lesions (substantia nigra, subthalamic nucleus, globus pallidus) | NCI, DN, NII | Neurodegenerative type | ||
| CBD (tau) | Uryu et al (30) | 39 | 15.4 | Hippocampus, entorhinal, temporal-frontal cortex | DN | Aging type | |
| Yokota et al (12) | 12 | 17 | Amygdala, hippocampus, entorhinal | NCI | Colocalization(−) | Aging type | |
| Kouri et al (31) | 1 | 100 | Olivary nucleus | NCI | |||
| Yamashita et al (32) | 1 | 100 | CBD lesions (cerebral cortex, pons, medulla oblongata) | NCI | Colocalization(+) | Neurodegenerative type | |
| Koga et al (33) | 187 | 45 | CBD lesions (midbrain tegmentum, subthalamic nucleus, pontine tegmentum, substantia nigra) | NCI | Neurodegenerative type | ||
| Sainouchi et al (34) | 10 | 90 | CBD lesions (putamen, globus pallidus, thalamus, subthalamic nucleus, pontine tegmentum) | NCI, GCI, DN | Colocalization(+) | Neurodegenerative type | |
| MSA (α-synuclein) | Geser et al (35) | 29 | rare | Amygdala, hippocampus, entorhinal | DN, GCI, NCI | Aging type | |
| Sousa et al (36) | 1 | 0 | None | ||||
| Koga et al (37) | 186 | 7 | Amygdala, hippocampus | GCI | Colocalization(+) | Aging type | |
| Nwabuobi et al (38) | 1 | 100 | Lenticular nucleus, paracentral cortex | NCI, GCI | Colocalization(+) | Aging type | |
| AGD (tau) | Fujishiro et al (39) | 15 | 60 | Amygdala, hippocampus, entorhinal | NCI, GCI | Aging type | |
| Uchino et al (20) | 11 | 54.5 | Hippocampus, amygdala | DN, NCI, GCI | Aging type | ||
| SCA2 | Toyoshima et al (14) | 1 | 100 | SCA2 lesions (motor cortex, thalamus, red nucleus, pons, inferior olive) | NCI | Neurodegenerative type | |
| SCA3 | Tan et al (40) | 10 | 100 | Cranial nucleus, spinal cord | NCI | Neurodegenerative type | |
| Huntington (polyglutamine) | Schwab et al (41) | 10 | 100 | Huntington lesions (frontal and temporal cortex) | NCI, DN | Colocalization(+) | Neurodegenerative type |
| Tada et al (42) | 4 | 100 | Huntington lesions (cerebral cortex, thalamus, hypoglossal nucleus, anterior horn) | NCI, DN | Colocalization(−) | Neurodegenerative type |
PD, Parkinson disease; DLB, Dementia with Lewy bodies; Guam PDC, Guam parkinsonism-dementia complex; PSP, progressive supranuclear palsy; CBD, cortico-basal degeneration; MSA, multiple system atrophy; AGD, argyrophilic grain disease; SCA2, spinocerebellar ataxia type 2; SCA3, spinocerebellar ataxia type 3; NCI, neuronal cytoplasmic inclusion; GCI, oligodendroglial cytoplasmic inclusion; DN, dystrophic neurite.
| Disease (Protein) . | Author (References) . | Number of Patients . | Proportion of Patients With pTDP-43 Expression (%) . | Brain Distribution of pTDP-43 . | Morphology of pTDP-43 . | Association With Disease Protein . | pTDP-43 Expression Type . |
|---|---|---|---|---|---|---|---|
| PD, DLB (α-synuclein) | Yasuda et al (17) | 10 | 10 | Hippocampus, entorhinal | NCI | Colocalizaion(+) | Aging type |
| Higashi et al (18) | 11 | 45 | Amygdala, hippocampus, entorhinal | NCI, DN | Aging type | ||
| Arai et al (19) | 15 | 53 | Amygdala, hippocampus, entorhinal | NCI, DN | Colocalization(+) | Aging type | |
| Uchino et al (20) | 11 | 72.7 | Hippocampus, amygdala, medulla | DN, NCI, GCI | Aging type | ||
| McAleese et al (21) | 15 | 33.3 | Amygdala, hippocampus | NCI | Aging type | ||
| Buciuc et al (22) | 395 | 37 | Hippocampus | not examined | |||
| Uemura et al (23) | 313 | 21 | Amygdala, hippocampus, entorhinal (LATE) | NCI | Aging type | ||
| Guam PDC (tau) | Hasegawa et al (24) | 6 | 100 | Hippocampus | NCI, DN | Aging type | |
| Geser et al (25) | 26 | 46.2 | Amygdala, hippocampus, entorhinal | NCI, GCI | Aging type | ||
| Miklossy et al (26) | 35 | 100 | Amygdala, hippocampus, entorhinal | NCI | Aging type | ||
| PSP (tau) | King et al (27) | 5 | 20 | Neocortex | NCI | Aging type | |
| Yokota et al (12) | 19 | 26 | Amygdala, hippocampus, entorhinal | NCI | Colocalization(+) | Aging type | |
| Kertesz et al (28) | 1 | 0 | None | ||||
| Koga et al (29) | 945 | 6 | Amygdala, hippocampus, PSP lesions (substantia nigra, subthalamic nucleus, globus pallidus) | NCI, DN, NII | Neurodegenerative type | ||
| CBD (tau) | Uryu et al (30) | 39 | 15.4 | Hippocampus, entorhinal, temporal-frontal cortex | DN | Aging type | |
| Yokota et al (12) | 12 | 17 | Amygdala, hippocampus, entorhinal | NCI | Colocalization(−) | Aging type | |
| Kouri et al (31) | 1 | 100 | Olivary nucleus | NCI | |||
| Yamashita et al (32) | 1 | 100 | CBD lesions (cerebral cortex, pons, medulla oblongata) | NCI | Colocalization(+) | Neurodegenerative type | |
| Koga et al (33) | 187 | 45 | CBD lesions (midbrain tegmentum, subthalamic nucleus, pontine tegmentum, substantia nigra) | NCI | Neurodegenerative type | ||
| Sainouchi et al (34) | 10 | 90 | CBD lesions (putamen, globus pallidus, thalamus, subthalamic nucleus, pontine tegmentum) | NCI, GCI, DN | Colocalization(+) | Neurodegenerative type | |
| MSA (α-synuclein) | Geser et al (35) | 29 | rare | Amygdala, hippocampus, entorhinal | DN, GCI, NCI | Aging type | |
| Sousa et al (36) | 1 | 0 | None | ||||
| Koga et al (37) | 186 | 7 | Amygdala, hippocampus | GCI | Colocalization(+) | Aging type | |
| Nwabuobi et al (38) | 1 | 100 | Lenticular nucleus, paracentral cortex | NCI, GCI | Colocalization(+) | Aging type | |
| AGD (tau) | Fujishiro et al (39) | 15 | 60 | Amygdala, hippocampus, entorhinal | NCI, GCI | Aging type | |
| Uchino et al (20) | 11 | 54.5 | Hippocampus, amygdala | DN, NCI, GCI | Aging type | ||
| SCA2 | Toyoshima et al (14) | 1 | 100 | SCA2 lesions (motor cortex, thalamus, red nucleus, pons, inferior olive) | NCI | Neurodegenerative type | |
| SCA3 | Tan et al (40) | 10 | 100 | Cranial nucleus, spinal cord | NCI | Neurodegenerative type | |
| Huntington (polyglutamine) | Schwab et al (41) | 10 | 100 | Huntington lesions (frontal and temporal cortex) | NCI, DN | Colocalization(+) | Neurodegenerative type |
| Tada et al (42) | 4 | 100 | Huntington lesions (cerebral cortex, thalamus, hypoglossal nucleus, anterior horn) | NCI, DN | Colocalization(−) | Neurodegenerative type |
| Disease (Protein) . | Author (References) . | Number of Patients . | Proportion of Patients With pTDP-43 Expression (%) . | Brain Distribution of pTDP-43 . | Morphology of pTDP-43 . | Association With Disease Protein . | pTDP-43 Expression Type . |
|---|---|---|---|---|---|---|---|
| PD, DLB (α-synuclein) | Yasuda et al (17) | 10 | 10 | Hippocampus, entorhinal | NCI | Colocalizaion(+) | Aging type |
| Higashi et al (18) | 11 | 45 | Amygdala, hippocampus, entorhinal | NCI, DN | Aging type | ||
| Arai et al (19) | 15 | 53 | Amygdala, hippocampus, entorhinal | NCI, DN | Colocalization(+) | Aging type | |
| Uchino et al (20) | 11 | 72.7 | Hippocampus, amygdala, medulla | DN, NCI, GCI | Aging type | ||
| McAleese et al (21) | 15 | 33.3 | Amygdala, hippocampus | NCI | Aging type | ||
| Buciuc et al (22) | 395 | 37 | Hippocampus | not examined | |||
| Uemura et al (23) | 313 | 21 | Amygdala, hippocampus, entorhinal (LATE) | NCI | Aging type | ||
| Guam PDC (tau) | Hasegawa et al (24) | 6 | 100 | Hippocampus | NCI, DN | Aging type | |
| Geser et al (25) | 26 | 46.2 | Amygdala, hippocampus, entorhinal | NCI, GCI | Aging type | ||
| Miklossy et al (26) | 35 | 100 | Amygdala, hippocampus, entorhinal | NCI | Aging type | ||
| PSP (tau) | King et al (27) | 5 | 20 | Neocortex | NCI | Aging type | |
| Yokota et al (12) | 19 | 26 | Amygdala, hippocampus, entorhinal | NCI | Colocalization(+) | Aging type | |
| Kertesz et al (28) | 1 | 0 | None | ||||
| Koga et al (29) | 945 | 6 | Amygdala, hippocampus, PSP lesions (substantia nigra, subthalamic nucleus, globus pallidus) | NCI, DN, NII | Neurodegenerative type | ||
| CBD (tau) | Uryu et al (30) | 39 | 15.4 | Hippocampus, entorhinal, temporal-frontal cortex | DN | Aging type | |
| Yokota et al (12) | 12 | 17 | Amygdala, hippocampus, entorhinal | NCI | Colocalization(−) | Aging type | |
| Kouri et al (31) | 1 | 100 | Olivary nucleus | NCI | |||
| Yamashita et al (32) | 1 | 100 | CBD lesions (cerebral cortex, pons, medulla oblongata) | NCI | Colocalization(+) | Neurodegenerative type | |
| Koga et al (33) | 187 | 45 | CBD lesions (midbrain tegmentum, subthalamic nucleus, pontine tegmentum, substantia nigra) | NCI | Neurodegenerative type | ||
| Sainouchi et al (34) | 10 | 90 | CBD lesions (putamen, globus pallidus, thalamus, subthalamic nucleus, pontine tegmentum) | NCI, GCI, DN | Colocalization(+) | Neurodegenerative type | |
| MSA (α-synuclein) | Geser et al (35) | 29 | rare | Amygdala, hippocampus, entorhinal | DN, GCI, NCI | Aging type | |
| Sousa et al (36) | 1 | 0 | None | ||||
| Koga et al (37) | 186 | 7 | Amygdala, hippocampus | GCI | Colocalization(+) | Aging type | |
| Nwabuobi et al (38) | 1 | 100 | Lenticular nucleus, paracentral cortex | NCI, GCI | Colocalization(+) | Aging type | |
| AGD (tau) | Fujishiro et al (39) | 15 | 60 | Amygdala, hippocampus, entorhinal | NCI, GCI | Aging type | |
| Uchino et al (20) | 11 | 54.5 | Hippocampus, amygdala | DN, NCI, GCI | Aging type | ||
| SCA2 | Toyoshima et al (14) | 1 | 100 | SCA2 lesions (motor cortex, thalamus, red nucleus, pons, inferior olive) | NCI | Neurodegenerative type | |
| SCA3 | Tan et al (40) | 10 | 100 | Cranial nucleus, spinal cord | NCI | Neurodegenerative type | |
| Huntington (polyglutamine) | Schwab et al (41) | 10 | 100 | Huntington lesions (frontal and temporal cortex) | NCI, DN | Colocalization(+) | Neurodegenerative type |
| Tada et al (42) | 4 | 100 | Huntington lesions (cerebral cortex, thalamus, hypoglossal nucleus, anterior horn) | NCI, DN | Colocalization(−) | Neurodegenerative type |
PD, Parkinson disease; DLB, Dementia with Lewy bodies; Guam PDC, Guam parkinsonism-dementia complex; PSP, progressive supranuclear palsy; CBD, cortico-basal degeneration; MSA, multiple system atrophy; AGD, argyrophilic grain disease; SCA2, spinocerebellar ataxia type 2; SCA3, spinocerebellar ataxia type 3; NCI, neuronal cytoplasmic inclusion; GCI, oligodendroglial cytoplasmic inclusion; DN, dystrophic neurite.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
